Login to Your Account

Stock drop explained; Zafgen reports patient death in PWS trial

Wednesday, October 14, 2015
For two days, industry observers watched as shares of Zafgen Inc. plummeted for no apparent reason, losing more than half their value and driving analysts to speculate that disappointing data lay ahead for the company's lead candidate, beloranib.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription